Skip to main content

Table 3 Relative miRNA expression levels of the 30 selected miRNAs between ER+ and ER− breast tumors in the validation series

From: MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?

Official name

Normal breast tissue (n = 8)

ER+ breast tumors (n = 85)

ER−breast tumors (n = 68)

ER+/ER−

FC

p-value

11 up-regulated miRNAs selected in the screening series

miR-190b

1.0 (0.32-1.57)

6.34 (0.71-32.3)

0.27 (0.02-6.23)

23.30

<0.0001

miR-101-1

1.0 (0.69-8.05)

0.30 (0.05-2.10)

0.15 (0.01-0.92)

2.01

<0.0001

miR-193b

1.0 (0.43-1.79)

1.44 (0.10-9.17)

1.00 (0.11-4.45)

1.43

0.0191

miR-342-5p

1.0 (0.78-2.16)

2.03 (0.29-19.4)

0.93 (0.10-3.65)

2.18

<0.0001

miR-376c

1.0 (0.52-3.04)

0.14 (0.02-1.55)

0.10 (0.02-0.83)

1.43

0.0064

miR-451

1.0 (0.32-11.1)

0.17 (0.02-14.0)

0.14 (0.01-9.77)

1.23

ns

miR-143

1.0 (0.45-2.72)

0.21 (0.03-1.40)

0.14 (0.02-0.74)

1.52

0.0140

miR-30c2

1.0 (0.69-1.72)

0.54 (0.12-3.06)

0.34 (0.09-1.17)

1.60

<0.0001

miR-30e

1.0 (0.70-2.98)

0.79 (0.12-4.57)

0.47 (0.10-2.28)

1.68

<0.0001

miR-26a1

1.0 (0.77-4.06)

0.34 (0.11-1.78)

0.09 (0.02-0.47)

3.64

<0.0001

miR-26b

1.0 (0.68-4.38)

0.49 (0.15-2.93)

0.34 (0.06-1.64)

1.44

0.0008

7 down-regulated miRNAs selected in the screening series

miR-654-3p

1.0 (0.72-1.34)

0.30 (0.05-2.68)

0.66 (0.04-17.8)

−2.16

<0.0001

miR-203

1.0 (0.51-2.43)

0.88 (0.02-5.78)

1.51 (0.05-19.6)

−1.72

0.0059

miR-146a

1.0 (0.54-3.71)

0.70 (0.07-3.63)

0.95 (0.10-4.30)

−1.36

0.0344

miR-494

1.0 (0.85-2.17)

0.65 (0.02-6.96)

0.69 (0.02-9.03)

−1.07

ns

miR-338-5p

1.0 (0.79-1.78)

0.84 (0.19-4.66)

0.96 (0.12-5.08)

−1.15

ns

miR-891a

1.0 (0.77-1.64)

1.37 (0.14-8.43)

2.07 (0.37-15.5)

−1.51

ns

miR-1244

1.0 (0.73-1.69)

1.23 (0.16-5.11)

2.34 (0.35-25.3)

−1.91

<0.0001

12 miRNAs selected from the literature

let-7a

1.0 (0.73-1.79)

0.58 (0.15-2.00)

0.47 (0.11-2.99)

1.24

0.0055

let-7b

1.0 (0.71-1.69)

0.53 (0.08-2.04)

0.31 (0.04-0.82)

1.75

<0.0001

miR-18a

1.0 (0.49-3.33)

0.50 (0.06-2.53)

1.12 (0.12-23.9)

−2.24

<0.0001

miR-18b

1.0 (0.47-4.45)

0.50 (0.07-3.52)

1.04 (0.13-25.3)

−2.07

<0.0001

miR-19a

1.0 (0.70-2.13)

0.34 (0.03-2.61)

0.42 (0.02-14.4)

−1.24

ns

miR-21

1.0 (0.49-5.26)

2.05 (0.41-16.6)

1.84 (0.21-9.53)

1.12

ns

miR-22

1.0 (0.38-4.51)

0.71 (0.12-12.9)

0.66 (0.09-3.36)

1.08

ns

miR-92a1

1.0 (0.68-1.40)

0.32 (0.10-1.17)

0.49 (0.09-8.95)

−1.54

<0.0001

miR-155

1.0 (0.55-4.24)

2.06 (0.52-10.9)

3.97 (0.35-32.0)

−1.93

<0.0001

miR-206

1.0 (0.01-2.28)

0.25 (0.02-7.71)

0.32 (0.01-2.74)

−1.29

ns

miR-221

1.0 (0.65-1.92)

0.40 (0.07-4.24)

0.53 (0.05-5.55)

−1.31

ns

miR-222

1.0 (0.63-2.30)

0.39 (0.06-2.68)

0.50 (0.04-3.88)

−1.28

ns

  1. Results in ER+ and ER− tumors are expressed as the median (range) of miRNA level relative to normal breast tissues. For each miRNA, we report the fold-change (FC) between ER+ and ER− tumors and the p-value associated to Mann–Whitney test (ns for not significant)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us